Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Launched by RICCARDO GUGLIELMO ·
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a nasal spray called esketamine works for people with treatment-resistant depression, which means their depression has not improved with usual treatments. The study looks at how the spray affects symptoms like mood, motivation, anxiety, and thinking, as well as how it influences daily life, including work and social activities. Researchers also want to understand why some people respond better to the treatment by looking at factors like genetics and brain imaging.
People of all genders who are adults with treatment-resistant depression may be eligible to join. Participants can expect to receive esketamine nasal spray as part of their care while doctors observe how it helps and monitor safety. The study is happening in real-world medical settings, aiming to learn how esketamine can best be used to improve quality of life for those who haven’t found relief with other treatments.
Gender
ALL
Eligibility criteria
About Riccardo Guglielmo
Riccardo Guglielmo is a clinical trial sponsor with expertise in overseeing and managing research studies aimed at advancing medical knowledge and patient care. Committed to upholding the highest standards of scientific integrity and regulatory compliance, Riccardo Guglielmo facilitates the development and execution of clinical trials that contribute to innovative therapeutic solutions and improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Elisa Briasco, MD
Principal Investigator
Unige
Elisa Cavanna, MD
Principal Investigator
Unige
Riccardo Guglielmo, MD
Study Chair
Unige
Gianluca Serafini, MD
Study Director
Unige
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported